Nobiletin |
Citrus depressa |
MCF-7 |
500 ml |
Reduces ERK1/2,
cyclin-D1, p21 upregulation, mTOR and AKT inhibition |
(50) |
Resveratrol |
Vitis vinifera |
4T1 |
IC50 = 93 µM (72 h) |
S-phase slowdown Cell cycle suppression, higher levels of apoptosis |
(51) |
Resveratrol
|
Vitis vinifera
|
SUM159/MCF10A/ MCF-7
|
100 mg/
kg/d)
|
Through inhibition of Wnt β -catenin
pathway
|
(52)
|
Resveratrol
|
Vitis vinifera
|
/ MDA-MB-
231/ MCF-7
|
10, 25, and
50 μM
|
Decrease in MMP-9, MMP-2, c-Myc, and Cyclin D1 expression, decrease in
Sox2 translation and stimulation of STAT3 and Akt
|
(53)
|
Curcumin |
Curcuma longa |
BT-474/ MDA-MB-231 |
1–25 µg/mL (72
h) |
Akt phosphorylation and MAPK stimulation, Decrease HER-2
oncoprotein, and Decrease NF-B |
(54) |
Curcumin
|
Curcuma longa
|
MDA-MB-
231
|
10, 20 and 30 μm/ml
|
Expression of EGFR and Induction of cell death
|
(55)
|
Curcumin |
Curcuma longa |
MCF-7 |
1, 5, 10, 30 and 50 M |
By
suppressing NF-B/ AP-1, MAPK, and PKC signaling, TPA causes MMP-9
overexpression |
(56) |
Curcumin
|
Curcuma longa
|
MDA-MB-
231/MCF-10F/
Tumor2
|
30 μM
|
Reduced expression of EMT-associated, Fibronectin, Slug, N-cadherin,
Twist1, Vimentin, AXL, and. E-cadherin/ proteins -catenin
|
(57)
|
EGCG |
Epigallocatechin gallate |
MDA-MB-231 |
≥ 75 µM (24 h) |
Reduce expression of -catenin, p-Akt, and cyclin D1, inactivate the
catenin signaling mechanism, Reduced proliferation of cells and
disruption of adhesion junction formation |
(58) |
Eugenol
|
Syzygium
aromaticum
|
, 0.25,
0.50, 0.75, 1.0 and 1.5 μM,
|
BT-20/ MDA-MB-231/
MDA-MB-
468
|
Inhibits NF-B signaling, thereby decreasing IL-8 and IL-6
production.
|
(59)
|
Baicalin
|
Scutellaria
baicalensis
|
MCF-7/
MDA-MB-231
|
0, 20 or 30 μM
|
Reduces NF-B- p65 protein synthesis and NF-B- elicited upregulation of
BCL2, BIRC3, BIRC2, and CCND1 expression
|
(60)
|
Artemisinin
(Artesunate)
|
Artemisia annua
|
MDA-MB-231
|
25, 50 and 100 µM (48 h)
|
Reduce Bcl-2, enhance Bax, G2/M-phase arrest Reduce Cyclin-B1 and
Cyclin-D1, heterochromatin agglutination, degeneration of mitochondrial
vacuoles; nuclear enlargement, Reduce the amount of organelles within
cells
|
(61)
|
Ellagic acid
|
Juglans regia
|
MCF-7
cells;
|
0, 10,
20 and 30 μg/mL
|
Reduces signaling of TGF-/Smads
|
(62)
|
Ginseng extract |
Ginseng |
MCF-7 |
100–400 µM (24 h) |
Reduce
Bcl-2, augment Bax, cytochrome c, and activated caspase-3,augment ROS
production |
(63) |
Oleuropein |
Olea europaea |
1.7 mg/day |
MCF-7 |
Blocking the
growth and proliferation of MCF-7 cell xenografts |
(64) |
Eupatorin
|
Eupatorium
semiserratum
|
MCF-7/MDA-MB-
231
|
20 μg/ml
|
By inhibiting the p-Akt pathway, and boosting the production of
SMAC/Diablo, cytochrome c, Bax, Bak1, Bad, and HIF1A
|
(65)
|
Emodin |
Aloe vera |
- |
IC50 = 8.6 µM |
Unique
energy-dependent pathway of drug uptake inducing apoptosis |
(66) |
Genistein
|
Glycine max
|
MCF-7
|
10 nM–10
μM
|
Through the downregulation of the Hedgehog-Gli1 Signaling
|
(67)
|
Genistein
|
Glycine max
|
MCF-7/MDA-MB
231/ MCF10a
|
18.5 μM
|
Elevated levels of BRCA2 and BRCA1 protein
|
(68)
|
Artesunate
|
Artemisia
annua
|
-
|
IC50 = 2.3 µM
|
VEGF expression reduction
|
(69)
|
Kaempferol |
Moringa oleifera |
MDA-MB231 |
50 μM |
Increase
the production of NRF2 and its enzyme NQO1 in MCF-7 cells, thereby
preventing oncogenesis |
(70) |
Kaempferol |
Moringa oleifera |
MCF-7 |
10 μM |
halts cell
cycle progression at the G2/M phase by inhibiting CDK1 |
(71) |
Betulinic acid |
Betula sp. |
- |
IC50 = 13.5 µM |
Induction of
the extrinsic apoptosis mechanism through increased levels of DR4, DR5,
and PARP cleavage |
(72) |
Icariin
|
Epimedium
sagitatum
|
MDA-MB-231
/4 T1
|
10 or 20 μM
|
Reduces the signaling cascade of NF-B and SIRT6
|
(73)
|
Betulin |
Betula sp. |
- |
IC50 = 30.7 µM |
Induction of the
extrinsic apoptosis cascade through increased levels of DR4, DR5, and
PARP cleavage |
(74) |
Isoliquiritigenin
|
Spatholobus
suberectus
|
MCF-7/
MDA-MB-231
/BT-549
|
10 μg/ml
|
By blocking β-catenin/
ABCG2 signaling.
|
(75)
|
Berberine
|
Berberis
vulgaris
|
-
|
IC50 = 25 µM
|
Activation of cell cycle arrest, a combined effect with
drugs/dose-dependent decrease in tumor volume and angiogenesis
|
(76)
|
Epicatechin
gallate
|
Camellia
sinensis
|
-
|
IC50 = 350 µM
|
Promote apoptosis in various types of cells of cancer
|
(77)
|
Morusin
|
Ramulus mori
|
MCF-10A/ MDA-MB-231/4 T1 /EMT6 and
MCF-7
|
1, 2, 4, 6 and 8 μg/ml
|
Lipoapoptosis and adipogenic transformation are mediated by PPAR and
C/EBP
|
(78)
|
Epigallocatechin
|
Camellia
sinensis
|
-
|
IC50 = 22 µM
|
Growth restriction
|
(79)
|
D Rhamnose
β-hederin
|
Clematis ganpiniana
|
MCF-7/ SUM1315/
MDA-MB-231/
BT474
|
5, 10, 20, 40
and 80 μg/ml
|
via inhibiting the pathway of PI3K and AKT and enhancing the ERK
pathway
|
(80)
|
Myricetin |
Camellia sinensis |
MDA-Mb-231 |
50 mg/kg |
By
suppressing the expression of MMP2/9 as well as ST6GALNAC5 proteins |
(81) |
Ingenol
mebutate
|
Euphorbia
peplus
|
-
|
IC50 = 23.9 µM
|
Necrotic mechanism
|
(82)
|
β-Elemene
|
Rhizoma Zedoariae
|
MDA-MB-231
/ MCF-7
|
0–320
μmol/L
|
inhibiting the aerobic glycolysis triggered by dimer formation of PKM2
and nuclear transfer
|
(83)
|
Dehydrocorydaline |
Corydali syanhusuo |
MDA-MB-231 |
20,30,
40, 50 or 100 μM |
By reducing BCL 2, CCND 1, BCL 3, and CDK1 and
enhancing the generation of pro-apoptotic proteins caspase9/3/8 |
(84) |
Theacrine
|
Theobroma
grandiflorum
|
MDA-MB-231
|
10–100
μM
|
EMT induced by TGF is inhibited
|
(85)
|
Bilobetin |
Ginkgo biloba |
|
IC50 = 57.6 µM |
Stopping the
cell cycle at the G2/M phase |
(86) |
Harmine
|
Peganum harmala
|
MDA-MB-231
and MCF-7
|
50, 100 or 150 μM
|
By decreasing pErk, Bcl2, pAkt, and TAZ expression
|
(87)
|
Isoginkgetin |
Ginkgo biloba |
- |
IC50 = 92.1 µM |
Stopping
the cell cycle at the G2/M phase |
(86) |
α-santalol
|
Santalum album
|
20, 40 μM
|
MDA-MB
231/ MCF-7
|
via suppressing the Wnt/-catenin signaling pathway
|
(88)
|
Licoagrochalcone
|
Glycyrrhiza
glabra
|
-
|
IC50 = 28.6 µM
|
Promotion of apoptosis and suppression of cell division
|
(89)
|
Astragaloside IV
|
Astragalus
membranaceus
|
MCF-7/MDA-MB-
231/
/ MDA-MB-468
|
40 and 80 μg/ml
|
prevent BC cell proliferation and metastasis via inducing expression of
TRHDE-AS1
|
(90)
|
Apigenin
|
Matricaria
chamomilla
|
-
|
IC50 = 100 µM
|
augmentation of the DR5 mechanism
|
(91)
|
Betulinic acid
|
Castanopsis
acuminatissima
|
MCF-7
|
50 μM
|
via reducing topoisomerase or cyclin, suppressing VEGF signaling,
decreasing SP and NF-B stimulation, and downregulating matrix
metalloprotease production
|
(92)
|
Chamomillol
|
Matricaria
chamomilla
|
-
|
IC50 = 300 µM
|
Repress angiogenesis by repressing expression proteins.
|
(93)
|
Cucurbitacin B
|
Cucurbeta pepo
|
MDA-MB-231
|
0.5
and 1 mg/kg
|
Reduce NF-B and STAT3
|
(94)
|
Lycorine
|
Narcissus
pseudonarcissus
|
MCF-7/T47D/ MDA-MB-
231
|
5 or 10 mg/kg
|
via interfering with the Src/FAK pathway
|
(95)
|
Ginsenoside |
Panax ginseng |
- |
IC50 = 30 µM |
Activation of
apoptosis and suppression of cell division |
(96) |
Citral
|
Cymbopogon citratus
|
MDA-MB-231
|
2.5, 5.0 and
10.0 μg/ml
|
Reducing the expression of aldehyde dehydrogenase 1A3
|
(97)
|
Borbonol
|
Persea
americana
|
-
|
IC50 = 20.5 µM
|
Inhibition of proliferation
|
(98)
|
Matrine
|
Sophora flavescens
|
MCF-7
|
2, 4, 8 and
10 mM
|
through the aggregation of light chain 3 II and reduced levels of p62,
phosphorylation of mTOR and AKT was suppressed
|
(99)
|
Germacrone |
Rhizoma curcumae |
MCF-7 |
100 or 200 μM |
via
inhibiting ER-driven gene expression |
(100) |
Salvicine |
Salvia prionitis |
|
IC50 = 1.4 µM |
Breaks two
strands of DNA through increasing TOP2 activity; prevents re-ligation |
(101) |
Noscapine
|
Papaver somniferum
|
MCF-10/
MCF-7/
MDA-MB-231
|
20, 40,
60, 80 and 100 μM
|
A decrease in the expression of the NF-B gene and protein, along with an
increase in the expression of the IB gene
|
(102)
|
Cepharanthine
|
Stephania
cepharantha
|
MDA-MB-231
and MCF-7
|
5 μM for MCF-7,4 μM for
MDA-MB-231
|
By disrupting AKT/mTOR signaling system
|
(103)
|
Ursolic acid
|
Ocimum tenuiflorum
|
MDA-MB-231
|
10.0 μg/
ml
|
Reduced EGFR, PI3K/Akt/mTOR, and ERK activity
|
(104)
|
Protocatechu
aldehyde
|
Salvia
miltiorrhiza
|
MCF-7 and MDA-MB-231
|
0, 5,10, 25, 50, or 100 lM
|
inhibits the expression of -catenin and cyclin D1
|
(105)
|
Silibinin
|
Silybum
marianum
|
-
|
IC50 = 24 µM
|
Apoptosis induction and cell cycle arrest
|
(106)
|
Piperlongumine |
Piper longum |
MCF-7/MDA-MB-231/MDA-MB-453 And
BT-549 |
6.25,12.5, 25, 50 and 100 lM |
Through decreasing Bcl-2, cyclin
D1, p-Akt, p53, p70S6K1, and 4E-BP1 expression and increasing cytochrome
c and Bax expression; by inhibiting the PI3K/Akt/mTOR signaling axis. |
(107) |
Gossypol
|
Gossypium
hirsutum
|
MDA-MB-231
/ MDA-MB-468
MM-231 / MM-468
|
0–100 μM
0–50 μM
|
Increases the expression of BNIP3, TNFRSF9, and
GADD45A
|
(108)
|
Silymarin
|
Silybum
marianum
|
-
|
IC50 = 75 µM
|
Interaction with the production of cell cycle regulators and apoptotic
proteins; activation of cell cycle arrest
|
(109)
|
Pterostilbene |
Cyanococcus |
MDA-MB-468 |
Dose:50 μM |
Reduces
phosphorylation of mTOR and AKT and decreases cyclin D1 expression |
(110) |
Paradol
|
Zingiber
officinale
|
-
|
IC50 = 20.4µM
|
Reduced cellular viability
|
(111)
|
Colchicine |
Colchicum autumnale |
MCF-7 |
0.3125, 0.625, 1.25,
2.5, 5, 10, 20 and 40 μg/ml |
through cells unable to exit the G2/M
phase. |
(112) |
Tanshinone-IIA |
Salvia miltiorrhiza |
MDA-MB-231 |
0, 3 and 6
μM |
Through inducing S-phase cell cycle arrest and boosting GSK3
expression, MMP expression is inhibited. |
(113) |
Shogaol
|
Zingiber
officinale
|
-
|
IC50 = 24.4 µM
|
Inhibitory activity
|
(114)
|
β-caryophyllene
oxide
|
Myrica rubra
|
MDA-MB-231
and MCF7
|
5–500 μM
|
Inhibition of NF-B
|
(115)
|